🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Registry-Based Cohort Study on the Clinical Outcomes of Spinal Cord Glioma Resection Via the Dorsolateral Sulcus Approach

Recruitingn/aAges 3 Years - 75 YearsAllBeijing Tiantan Hospital
NCT07066475 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Spinal cord gliomas are the most common type of primary intramedullary malignant tumors, with a low incidence and a peak onset age of approximately 35 years. They are slightly more prevalent in males than females. Clinical manifestations vary depending on tumor characteristics and location, typically presenting with axial pain and displaying a tendency for unilateral, infiltrative growth. Prognosis is generally poor, and effective treatment options are limited aside from surgical resection. Common surgical approaches for intramedullary tumor removal include the posterior median sulcus approach, the dorsolateral sulcus approach, and surface entry techniques. Preliminary clinical observations suggest that the dorsolateral sulcus approach may offer superior preservation of neurological function and quality of life. However, due to limited research evaluating the safety and efficacy of diff

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age between 3 and 75 years 2. Undergoing surgical resection of spinal cord tumor 3. Histopathological diagnosis of spinal cord glioma based on routine pathological examination 4. Availability of complete clinical data and willingness to participate in follow-up 5. Informed consent obtained from the patient and/or legal guardians or immediate family members Exclusion Criteria: 1. Age under 3 years or over 75 years 2. Receipt of radiotherapy, chemotherapy, or anti-tumor biological therapy within 1 month prior to enrollment 3. Receipt of immunotherapy within 3 months prior to enrollment 4. Participation in other clinical trials within 3 months prior to enrollment 5. History of severe allergic reactions or known allergy-prone constitution 6. Pregnant or breastfeeding women, or individuals of childbearing potential not using adequate contraception 7. Presence of other severe medical conditions or uncontrolled infections 8. History of drug abuse, substance misuse, chronic alcoholism, or HIV infection 9. Uncontrolled epileptic seizures or psychiatric disorders resulting in loss of self-control
💊

What it tests

  • Not listed
📍

Where

1 site
Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy